HEALTH IN TECH, INC.

The quarter's revenue decline was attributed to onboarding and policy effective-date timing, but the company is asking investors to prioritize non-GAAP-style visibility metrics over the reported revenue trend. The explanation remains difficult to validate without customer-level, carrier-level, or subsequent-quarter evidence.

Management's pipeline conversion range of 15%-40% implies substantial uncertainty. Of the $66.3 million pipeline, only $1.9 million was already contracted; the remainder was still quoting or binding, so pipeline value should not be treated as backlog.

The CFO did not fully bridge the $17.3 million of first-half recognized contracted revenue plus $14 million expected in the second half to the $45 million-$50 million FY2026 guidance, instead relying on five more months of new sales and pipeline expansion.

Profitability deteriorated materially: adjusted EBITDA shifted from positive $1.6 million to negative $1.3 million, while operating expenses rose to $7.3 million. With $2.9 million of operating cash use in Q2 and $6.5 million of cash, further investment could create financing or dilution risk.

Accounts receivable days rose sharply to 55 from 20 a year earlier. Management cited historical improvement, but did not identify the current cause, expected normalization date, or whether the increase reflects carrier concentration or collection risk.

The claimed 20%-30% increase from obtaining an A-rated carrier is an aspiration rather than committed guidance, and management did not quantify the business currently blocked by the rating requirement.

The company capitalized $0.8 million of software development costs while reporting accelerating losses; investors should monitor capitalization policy, cash conversion, and whether platform investments produce measurable customer or revenue gains.